Dacomitinib Nitroso
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds. Dacomitinib is used to treat non-small cell lung cancer that has spread (metastatic) with an epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutation gene. Your doctor will use a test to check for the mutation before you receive this medicine.Dacomitinib Nitroso is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Dacomitinib Nitroso CAS NO:NA chemically represented as (E)-N-(4-((3-Chloro-4-fluorophenyl)(nitroso)amino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide . Synchemia is the leading manufacturing and exporter of Dacomitinib Nitroso . We supply Dacomitinib Nitroso with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0142868 |
| CAS No | NA |
| Mol.F. | C21H20N4O5 |
| Mol.Wt. | 408.41 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142869 |
| CAS No | NA |
| Mol.F. | C21H22N4O6 |
| Mol.Wt. | 426.43 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142870 |
| CAS No | 52322-22-2 |
| Mol.F. | C10H22N4O4 |
| Mol.Wt. | 262.3 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142871 |
| CAS No | 78213-39-5 |
| Mol.F. | C10H23N3O3 |
| Mol.Wt. | 233.3 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142872 |
| CAS No | NA |
| Mol.F. | C10H23N3O3 |
| Mol.Wt. | 233.3 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142873 |
| CAS No | NA |
| Mol.F. | C10H19N3O5 |
| Mol.Wt. | 261.28 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142874 |
| CAS No | NA |
| Mol.F. | C17H25F3N4O2 |
| Mol.Wt. | 374.4 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142875 |
| CAS No | NA |
| Mol.F. | C17H24F3N3O2 |
| Mol.Wt. | 359.39g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142876 |
| CAS No | NA |
| Mol.F. | C19H22F3N3O6 |
| Mol.Wt. | 445.40 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142877 |
| CAS No | NA |
| Mol.F. | C20H28F3N3O5 |
| Mol.Wt. | 447.46 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142878 |
| CAS No | NA |
| Mol.F. | C16H18F3N3O5 |
| Mol.Wt. | 389.33 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142879 |
| CAS No | NA |
| Mol.F. | C16H23F3N4O3 |
| Mol.Wt. | 376.38 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0142880 |
| CAS No | NA |
| Mol.F. | C15H22F3N3O4 |
| Mol.Wt. | 365.35g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142881 |
| CAS No | NA |
| Mol.F. | C19H22F3N3O6 |
| Mol.Wt. | 445.40 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142882 |
| CAS No | NA |
| Mol.F. | C17H20N2O5 |
| Mol.Wt. | 332.36 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142883 |
| CAS No | NA |
| Mol.F. | C17H18N2O5 |
| Mol.Wt. | 330.34 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |